Pub Date : 2024-08-01DOI: 10.1016/S2352-3026(24)00219-9
Siana Nkya, Upendo Masamu, Patience Kuona, Sarah Kiguli, Aldiouma Guindo, Fred Stephen Sarfo, Obiageli Nnodu, Ambroise Wonkam, Emmanuel Balandya, Julie Makani
{"title":"Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health.","authors":"Siana Nkya, Upendo Masamu, Patience Kuona, Sarah Kiguli, Aldiouma Guindo, Fred Stephen Sarfo, Obiageli Nnodu, Ambroise Wonkam, Emmanuel Balandya, Julie Makani","doi":"10.1016/S2352-3026(24)00219-9","DOIUrl":"10.1016/S2352-3026(24)00219-9","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"11 8","pages":"e565-e566"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-07-10DOI: 10.1016/S2352-3026(24)00174-1
Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela A Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im, Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St Pierre, Karin Burock, Yvonne Smith, Karen Sinclair, Cristina Diaz-de-Heredia
<p><strong>Background: </strong>Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie, <18 years) with moderate-to-severe chronic GVHD.</p><p><strong>Methods: </strong>In this single-arm, phase 2 study, patients were recruited at 21 hospitals or clinics across 14 countries in Asia, Europe, and Canada. Eligible patients were aged 28 days to younger than 18 years, had undergone allogenic HSCT, and had been diagnosed with treatment-naive or corticosteroid-refractory moderate-to-severe chronic GVHD, per 2014 National Institutes of Health consensus criteria. Patients received oral ruxolitinib dosing on the basis of their age at the start of treatment: those aged 12 years to younger than 18 years received 10 mg twice daily (age ≥12 to <18 years group), those aged 6 years to younger than 12 years (age ≥6 to <12 years group) received 5 mg twice daily, and those aged 2 years to younger than 6 years received 4 mg/m<sup>2</sup> twice daily (age ≥2 to <6 years group). Treatment was to be administered in 28-day cycles for approximately 36 months, alongside supportive treatment per institutional guidelines. The primary activity endpoint was overall response rate at cycle 7 day 1. Activity and safety analyses are reported in the full analysis set, which included all patients who received at least one dose of ruxolitinib. Here we report the prespecified interim analysis, scheduled to occur after all patients had completed 1 year of treatment or discontinued treatment, and the results for the primary endpoint evaluation reported here is to be considered final. This study is registered with ClinicalTrials.gov, NCT03774082, enrolment is complete, and the study is ongoing.</p><p><strong>Findings: </strong>Between May 20, 2020, and Sept 17, 2021, 48 patients were screened, of whom 45 were enrolled and received at least one dose of study drug (median age was 11·0 years [IQR 7·2-14·3], 16 [36%] were female, 29 [64%] were male, 21 [47%] were White, one [2%] was Black or African American, 23 [51%] were Asian, 17 [38%] were treatment-naive, 28 [62%] were corticosteroid-refractory). As of data cutoff (Oct 19, 2022), after a median ruxolitinib exposure of 55·1 weeks (IQR 13·1-75·3), the overall response rate at cycle 7 day 1 was 40·0% (18 of 45; 90% CI 27·7-53·3), with responses seen in seven (41%) of 17 treatment-naive patients and 11 (39%) of 28 corticosteroid-refractory patients. The most common treatment-related adverse events of grade 3 or worse were neutropenia (eight [18%] of 45) and thrombocytopenia (six [13%]). Seven (16%) patients had grade 3 or worse serious treatment-related adverse events; the most common was hyponatraemia (two [4%] of 45). Three (7%) patients died while on-treatment (within 30 days of treatment disco
背景：慢性移植物抗宿主疾病（GVHD）是异基因造血干细胞移植（HSCT）的一种致残性并发症，有时甚至危及生命。我们的目的是研究鲁索利替尼在皮质类固醇治疗中的活性、药代动力学和安全性：在这项单臂2期研究中，亚洲、欧洲和加拿大14个国家的21家医院或诊所招募了患者。符合条件的患者年龄在28天至18岁之间，接受过异基因造血干细胞移植，并根据2014年美国国立卫生研究院共识标准被诊断为无治疗或皮质类固醇难治性中重度慢性GVHD。患者根据开始治疗时的年龄接受鲁索利替尼口服给药：年龄在12岁至18岁以下的患者每天两次，每次10毫克（年龄≥12岁的患者每天两次，每次2毫克），年龄≥2岁至18岁的患者每天两次，每次2毫克（年龄≥18岁的患者每天两次，每次2毫克）：2020年5月20日至2021年9月17日期间，共筛选出48名患者，其中45名患者入组并接受了至少一次剂量的研究药物治疗（中位年龄为11-0岁[IQR 7-2-14-3]，16名[36%]为女性，29名[64%]为男性，21名[47%]为白人，1名[2%]为黑人或非裔美国人，23名[51%]为亚裔，17名[38%]为未接受治疗者，28名[62%]为皮质类固醇难治性患者）。截至数据截止日（2022年10月19日），中位ruxolitinib暴露55-1周（IQR 13-1-75-3）后，第7周期第1天的总体应答率为40-0%（45例中有18例；90% CI 27-7-53-3），17例非治疗依赖患者中有7例（41%）出现应答，28例皮质类固醇难治患者中有11例（39%）出现应答。最常见的3级或更严重的治疗相关不良反应是中性粒细胞减少（45例中有8例[18%]）和血小板减少（6例[13%]）。7名患者（16%）出现了3级或更严重的严重治疗相关不良事件；最常见的是低钠血症（45人中有2人[4%]）。3名（7%）患者在治疗期间（治疗停止后30天内）死亡，其中1人死于曲霉菌感染，1人死于脓毒性休克，1人死于急性呼吸窘迫综合征；均不认为与研究药物有关：在最终分析之前，这项研究表明，对于年龄在2岁至18岁之间的慢性GVHD患者，无论是无治疗史还是皮质类固醇难治性患者，Ruxolitinib都具有良好的活性和耐受性，因此支持在这一患者群体中使用Ruxolitinib。Ruxolitinib在这一患者群体中的安全性与成人一致。这项研究的最终分析结果将进一步说明Ruxolitinib在慢性GVHD儿童患者中的长期疗效：Novartis.
{"title":"Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.","authors":"Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela A Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im, Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St Pierre, Karin Burock, Yvonne Smith, Karen Sinclair, Cristina Diaz-de-Heredia","doi":"10.1016/S2352-3026(24)00174-1","DOIUrl":"10.1016/S2352-3026(24)00174-1","url":null,"abstract":"<p><strong>Background: </strong>Chronic graft-versus-host disease (GVHD) is a debilitating, and sometimes life threatening, complication of allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the activity, pharmacokinetics, and safety of ruxolitinib added to corticosteroids in paediatric patients (ie, <18 years) with moderate-to-severe chronic GVHD.</p><p><strong>Methods: </strong>In this single-arm, phase 2 study, patients were recruited at 21 hospitals or clinics across 14 countries in Asia, Europe, and Canada. Eligible patients were aged 28 days to younger than 18 years, had undergone allogenic HSCT, and had been diagnosed with treatment-naive or corticosteroid-refractory moderate-to-severe chronic GVHD, per 2014 National Institutes of Health consensus criteria. Patients received oral ruxolitinib dosing on the basis of their age at the start of treatment: those aged 12 years to younger than 18 years received 10 mg twice daily (age ≥12 to <18 years group), those aged 6 years to younger than 12 years (age ≥6 to <12 years group) received 5 mg twice daily, and those aged 2 years to younger than 6 years received 4 mg/m<sup>2</sup> twice daily (age ≥2 to <6 years group). Treatment was to be administered in 28-day cycles for approximately 36 months, alongside supportive treatment per institutional guidelines. The primary activity endpoint was overall response rate at cycle 7 day 1. Activity and safety analyses are reported in the full analysis set, which included all patients who received at least one dose of ruxolitinib. Here we report the prespecified interim analysis, scheduled to occur after all patients had completed 1 year of treatment or discontinued treatment, and the results for the primary endpoint evaluation reported here is to be considered final. This study is registered with ClinicalTrials.gov, NCT03774082, enrolment is complete, and the study is ongoing.</p><p><strong>Findings: </strong>Between May 20, 2020, and Sept 17, 2021, 48 patients were screened, of whom 45 were enrolled and received at least one dose of study drug (median age was 11·0 years [IQR 7·2-14·3], 16 [36%] were female, 29 [64%] were male, 21 [47%] were White, one [2%] was Black or African American, 23 [51%] were Asian, 17 [38%] were treatment-naive, 28 [62%] were corticosteroid-refractory). As of data cutoff (Oct 19, 2022), after a median ruxolitinib exposure of 55·1 weeks (IQR 13·1-75·3), the overall response rate at cycle 7 day 1 was 40·0% (18 of 45; 90% CI 27·7-53·3), with responses seen in seven (41%) of 17 treatment-naive patients and 11 (39%) of 28 corticosteroid-refractory patients. The most common treatment-related adverse events of grade 3 or worse were neutropenia (eight [18%] of 45) and thrombocytopenia (six [13%]). Seven (16%) patients had grade 3 or worse serious treatment-related adverse events; the most common was hyponatraemia (two [4%] of 45). Three (7%) patients died while on-treatment (within 30 days of treatment disco","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e580-e592"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-07-10DOI: 10.1016/S2352-3026(24)00206-0
Luisa Sisinni
{"title":"Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?","authors":"Luisa Sisinni","doi":"10.1016/S2352-3026(24)00206-0","DOIUrl":"10.1016/S2352-3026(24)00206-0","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e553-e555"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-07-04DOI: 10.1016/S2352-3026(24)00214-X
Yaiza Del Pozo Martín, Emma Cookson
{"title":"European Hematology Association 2024 Hybrid Congress.","authors":"Yaiza Del Pozo Martín, Emma Cookson","doi":"10.1016/S2352-3026(24)00214-X","DOIUrl":"10.1016/S2352-3026(24)00214-X","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e561-e562"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-07-01DOI: 10.1016/S2352-3026(24)00175-3
Akshay Sharma, Tami D John
{"title":"Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease.","authors":"Akshay Sharma, Tami D John","doi":"10.1016/S2352-3026(24)00175-3","DOIUrl":"10.1016/S2352-3026(24)00175-3","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e556-e559"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141535732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01DOI: 10.1016/S2352-3026(24)00216-3
Jo McIntyre
{"title":"Needles were the least of my worries.","authors":"Jo McIntyre","doi":"10.1016/S2352-3026(24)00216-3","DOIUrl":"https://doi.org/10.1016/S2352-3026(24)00216-3","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":"11 8","pages":"e564"},"PeriodicalIF":15.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-05-30DOI: 10.1016/S2352-3026(24)00132-7
Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, Montserrat Arnan, Rosa Coll, Sara Garcia-Avila, Evelyn Acuña-Cruz, Isabel Cano, Tim C P Somervaille, Sonia Gutierrez, María Isabel Arévalo, Jordi Xaus, Carlos Buesa, Ana Limón, Douglas V Faller, Francesc Bosch, Pau Montesinos
<p><strong>Background: </strong>Iadademstat is a potent, selective, oral inhibitor of both the enzymatic and scaffolding activities of the transcriptional repressor lysine-specific demethylase 1 (LSD1; also known as KDM1A) that showed promising early activity and safety in a phase 1 trial and strong preclinical synergy with azacitidine in acute myeloid leukaemia cell lines. Therefore, we aimed to investigate the combination of iadademstat and azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia.</p><p><strong>Methods: </strong>The open-label, phase 2a, dose-finding ALICE study was conducted at six hospitals in Spain and enrolled patients aged 18 years or older with newly diagnosed acute myeloid leukaemia not eligible for intensive chemotherapy and an ECOG performance status of 0-2. In the dose escalation portion of the trial, patients received a starting dose of iadademstat at 90 μg/m<sup>2</sup> per day (with de-escalation to 60 μg/m<sup>2</sup> per day and escalation up to 140 μg/m<sup>2</sup> per day) orally, for 5 days on, 2 days off weekly, with azacitidine 75 mg/m<sup>2</sup> subcutaneously, for seven of 28 days. The primary objectives were safety (analysed in the safety analysis set; all patients who received at least one dose of study treatment) and establishing the recommended phase 2 dose; secondary objectives included response rates in the efficacy analysis set (all patients who had at least one efficacy assessment). This study is registered on EudraCT (EudraCT 2018-000482-36) and has been completed.</p><p><strong>Findings: </strong>Between Nov 12, 2018, and Sept 30, 2021, 36 patients with newly diagnosed acute myeloid leukaemia were enrolled; the median age was 76 (IQR 74-79) years, all patients were White, 18 (50%) were male, and 18 (50%) were female, and all had intermediate-risk or adverse-risk acute myeloid leukaemia. The median follow-up was 22 (IQR 16-31) months. The most frequent (≥10%) adverse events considered to be related to treatment were decreases in platelet (25 [69%]) and neutrophil (22 [61%]) counts (all grade 3-4) and anaemia (15 [42%]; of which ten [28%] were grade 3-4). Three patients had treatment-related serious adverse events (one fatal grade 5 intracranial haemorrhage, one grade 3 differentiation syndrome, and one grade 3 febrile neutropenia). Based on safety, pharmacokinetic and pharmacodynamic data, and efficacy, the recommended phase 2 dose of iadademstat was 90 μg/m<sup>2</sup> per day with azacitidine. 22 (82%; 95% CI 62-94) of 27 patients in the efficacy analysis set had an objective response. 14 (52%) of 27 patients had complete remission or complete remission with incomplete haematological recovery; of these, ten of 11 evaluable for measurable residual disease achieved negativity. In the safety analysis set, 22 (61%) of 36 patients had an objective response.</p><p><strong>Interpretation: </strong>The combination of iadademstat and azacitidine has a manageable safet
{"title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.","authors":"Olga Salamero, Antonieta Molero, José Antonio Pérez-Simón, Montserrat Arnan, Rosa Coll, Sara Garcia-Avila, Evelyn Acuña-Cruz, Isabel Cano, Tim C P Somervaille, Sonia Gutierrez, María Isabel Arévalo, Jordi Xaus, Carlos Buesa, Ana Limón, Douglas V Faller, Francesc Bosch, Pau Montesinos","doi":"10.1016/S2352-3026(24)00132-7","DOIUrl":"10.1016/S2352-3026(24)00132-7","url":null,"abstract":"<p><strong>Background: </strong>Iadademstat is a potent, selective, oral inhibitor of both the enzymatic and scaffolding activities of the transcriptional repressor lysine-specific demethylase 1 (LSD1; also known as KDM1A) that showed promising early activity and safety in a phase 1 trial and strong preclinical synergy with azacitidine in acute myeloid leukaemia cell lines. Therefore, we aimed to investigate the combination of iadademstat and azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia.</p><p><strong>Methods: </strong>The open-label, phase 2a, dose-finding ALICE study was conducted at six hospitals in Spain and enrolled patients aged 18 years or older with newly diagnosed acute myeloid leukaemia not eligible for intensive chemotherapy and an ECOG performance status of 0-2. In the dose escalation portion of the trial, patients received a starting dose of iadademstat at 90 μg/m<sup>2</sup> per day (with de-escalation to 60 μg/m<sup>2</sup> per day and escalation up to 140 μg/m<sup>2</sup> per day) orally, for 5 days on, 2 days off weekly, with azacitidine 75 mg/m<sup>2</sup> subcutaneously, for seven of 28 days. The primary objectives were safety (analysed in the safety analysis set; all patients who received at least one dose of study treatment) and establishing the recommended phase 2 dose; secondary objectives included response rates in the efficacy analysis set (all patients who had at least one efficacy assessment). This study is registered on EudraCT (EudraCT 2018-000482-36) and has been completed.</p><p><strong>Findings: </strong>Between Nov 12, 2018, and Sept 30, 2021, 36 patients with newly diagnosed acute myeloid leukaemia were enrolled; the median age was 76 (IQR 74-79) years, all patients were White, 18 (50%) were male, and 18 (50%) were female, and all had intermediate-risk or adverse-risk acute myeloid leukaemia. The median follow-up was 22 (IQR 16-31) months. The most frequent (≥10%) adverse events considered to be related to treatment were decreases in platelet (25 [69%]) and neutrophil (22 [61%]) counts (all grade 3-4) and anaemia (15 [42%]; of which ten [28%] were grade 3-4). Three patients had treatment-related serious adverse events (one fatal grade 5 intracranial haemorrhage, one grade 3 differentiation syndrome, and one grade 3 febrile neutropenia). Based on safety, pharmacokinetic and pharmacodynamic data, and efficacy, the recommended phase 2 dose of iadademstat was 90 μg/m<sup>2</sup> per day with azacitidine. 22 (82%; 95% CI 62-94) of 27 patients in the efficacy analysis set had an objective response. 14 (52%) of 27 patients had complete remission or complete remission with incomplete haematological recovery; of these, ten of 11 evaluable for measurable residual disease achieved negativity. In the safety analysis set, 22 (61%) of 36 patients had an objective response.</p><p><strong>Interpretation: </strong>The combination of iadademstat and azacitidine has a manageable safet","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e487-e498"},"PeriodicalIF":15.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141200334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01Epub Date: 2024-06-07DOI: 10.1016/S2352-3026(24)00182-0
Elizabeth Gourd
{"title":"Infected blood scandal linked to more than 3000 deaths.","authors":"Elizabeth Gourd","doi":"10.1016/S2352-3026(24)00182-0","DOIUrl":"10.1016/S2352-3026(24)00182-0","url":null,"abstract":"","PeriodicalId":48726,"journal":{"name":"Lancet Haematology","volume":" ","pages":"e481-e482"},"PeriodicalIF":15.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：